913168-10-2

Usage

Uses

Used in Chemical Research:
Benzo[d][1,2,3]triazol-1-yl-2-(2-(pyridin-2-yl)disulfanyl) ethyl carbonate is utilized as a research tool in chemical studies, where its unique structure can be explored for understanding molecular interactions and the development of new methodologies.
Used in Drug Development:
In the pharmaceutical industry, Benzo[d][1,2,3]triazol-1-yl-2-(2-(pyridin-2-yl)disulfanyl) ethyl carbonate is employed as a lead compound for drug development. Its potential biological and pharmacological activities make it a promising candidate for further research and the creation of novel therapeutic agents.
Further research is necessary to fully elucidate the chemical properties and potential applications of Benzo[d][1,2,3]triazol-1-yl-2-(2-(pyridin-2-yl)disulfanyl) ethyl carbonate, ensuring its safe and effective use in various fields.

Upstream product

• 111625-28-6 2-(2-(Pyridin-2-yl)disulfanyl)ethanol 
• 2592-95-2 benzotriazol-1-ol 
• 503-38-8 trichloromethyl chloroformate 
• 32315-10-9 bis(trichloromethyl) carbonate 
• 2637-34-5 2-Sulfanylpyridine 
• 118930-99-7 2-(2-hydroxyethyl)disulfanylpyridine hydrochloride 
• 892402-96-9 (1-chloroformyloxy)ethyl 2-pyridinyl disulfide 

Downstream Products

• 1048378-93-3 C₅₉H₈₆N₂O₁₅S₂ 
• 1312678-90-2 everolimus (2'-pyridyldisulfanyl)ethyl carbonate 
• 1218756-66-1 C₂₇H₂₉N₁₁O₆S₂ 
• 1219142-62-7 C₃₁H₃₇N₁₁O₆S₂ 

Relevant academic research and scientific papers

CONJUGATION OF MCR1 LIGAND WITH CYTOTOXIC DRUGS FOR TREATING SKIN CANCER

Ligand-drug conjugates for targeted melanoma therapies are disclosed herein. A ligand is conjugated to a cytotoxic cancer drug through a cleavage linker. The ligand can bind to an overexpressed receptor on a cancer cell, resulting in selectivity. This allows the drug to enter a cancer cell selectively and release the drug within that specific cancer cell. Such therapies provide selectivity to melanoma through a ligand that targets the MC1R receptor, which is highly expressed in 80% of malignant melanomas. The ligand-drug conjugates can be used to deliver a wide range of cytotoxic cancer drugs selective to melanoma cells which may solve the drug resistance problem of melanoma in current therapies.

Novel mTOR inhibitor compounds and the use thereof

The novel mTOR inhibitor compounds of the present invention are capable of selective drug delivery to bone and released slowly in bone for a long period of time. The present invention relates to a targeted compound linked to a mTOR inhibitory bone disease therapeutic agent.

Novel mTOR inhibitor compounds and the use thereof

The novel mTOR inhibitor compounds of the present invention are capable of selective drug delivery to bone and released slowly in bone for a long period of time. The present invention relates to a targeted compound linked to a mTOR inhibitory bone disease therapeutic agent.

HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF

Conjugates of an active agent attached to a targeting moiety, such as an HSP90 binding moiety, via a linker, and particles comprising such conjugates have been designed. Such conjugates and particles can provide improved temporospatial delivery of the active agent, improved biodistribution and penetration in tumor, and/or decreased toxicity. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer.

A Stepwise Approach for the Synthesis of Folic Acid Conjugates with Protein Kinase Inhibitors

Herein, we report an alternative synthetic approach for selected 2,6,9-trisubstituted purine CDK inhibitor conjugates with folic acid as a drug-delivery system targeting folate receptors. In contrast to the previously reported approaches, the desired conj

NEUROTENSIN RECEPTOR BINDING CONJUGATES AND FORMULATIONS THEREOF

Conjugates of an active agent attached to a neurotensin receptor-binding targeting moiety via a linker have been designed. Nanoparticles and microparticles comprising such conjugates can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or other diseases.

PENICILLAMINE CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF

Conjugates of an active agent attached to a targeting moiety via a penicillamine linker, and particles comprising such conjugates have been designed. Such conjugates and particles can provide increased stability and improved temporospatial delivery of the active agent, improved biodistribution and penetration in tumor, and/or decreased toxicity. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer.

TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF

Particles, including nanoparticles and microparticles, and pharmaceutical formulations thereof, comprising conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety via a linker have been designe

DUPA Conjugation of a Cytotoxic Indenoisoquinoline Topoisomerase i Inhibitor for Selective Prostate Cancer Cell Targeting

(Figure Presented). Prostate-specific membrane antigen (PSMA) is overexpressed in most prostate cancer cells while being present at low or undetectable levels in normal cells. This difference provides an opportunity to selectively deliver cytotoxic drugs

PROCESSES FOR MAKING EPOTHILONE COMPOUNDS AND ANALOGS

The present invention relates to processes for making epothilone compounds and analogs thereof, such as epi-epothilone A or epi-epothilone B, and aziridinyl-epothilone analogs.